Hamza Almusabeh

Dr. Hamza Almusabeh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in Children
Verified
Journal Article
Open access
PDF file
Abdullah A YousefAbdullah A Yousef
Abdullah A Yousef
HSHwazen Shash
Hwazen Shash
AAAli N. Almajid
Ali N. Almajid
ABAmmar A. Binammar
Ammar A. Binammar
HAHamza Almusabeh
Hamza Almusabeh
WAWaleed H. Albuali
Waleed H. Albuali
Acute chest syndrome (ACS) is a common cause of death in sickle cell disease (SCD) patients. Multiple studies investigated the risk factors of developing ACS; however, predictors of recurrent ACS episodes have not been thoroughly investigated. We aim to examine the clinical and laboratory predictors of recurrent ACS in pediatric patients with SCD. A retrospective case-control study included pediatric patients with SCD (˂14 years) admitted with ACS or developed ACS during admission for another indication. Patients were classified into recurrent ACS episodes (≥2 episodes) and a single ACS episode groups. Ninety-one ACS episodes (42 patients) were included, with a mean age at diagnosis of 7.18 ± 3.38 years. Twenty-two (52.4%) patients were male, and twenty-five (59.5%) patients had recurrent ACS. Younger age at first ACS was significantly associated with recurrence (p = 0.003), with an optimal cutoff at 7.5 years (area under the receiver operating characteristic curve [AUROC] = 0.833; p < 0.001). Higher SCD-related hospitalizations were significantly associated with recurrence (p = 0.038). Higher mean values of baseline white blood count (WBC) (p = 0.009), mean corpuscular volume (MCV) (p = 0.011), and reticulocyte (p = 0.036) were significantly associated with recurrence. Contrarily, lower baseline hematocrit values (p = 0.016) were significantly associated with recurrence. The ACS frequencies were significantly lower after hydroxyurea (p = 0.021). The odds of ACS recurrence increased with a positive C-reactive protein (CRP) at admission (p = 0.006). In conclusion, several baseline and admission laboratory data showed significant associations with recurrence. Hydroxyurea therapy demonstrated reduced ACS episodes.

25 March 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
HAHamza Almusabeh
Hamza Almusabeh
ZKZack Kovach
Zack Kovach
LLLaurel Lloyd
Laurel Lloyd
MAMohamad Zaki Alzaher
Mohamad Zaki Alzaher
DTDaniel Teran
Daniel Teran
JHJennifer Hadam-Veverka
Jennifer Hadam-Veverka

1 November 2025 in ACG Case Reports Journal
Verified
Journal Article
Open access
OAOlanrewaju Adeniran
Olanrewaju Adeniran
VCVibhu Chittajallu
Vibhu Chittajallu
HAHamza Almusabeh
Hamza Almusabeh
SASulaiman Abdullahi
Sulaiman Abdullahi
HQHuzaifah Qureshi
Huzaifah Qureshi
SSShailendra Singh
Shailendra Singh
We describe a case of symptomatic pancreatic insulinoma in an 80-year-old man with multiple comorbidities. The patient underwent endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA). After biochemical suspicion of endogenous hyperinsulinemic hypoglycemia, imaging revealed a 9 × 18 mm pancreatic body mass confirmed as a World Health Organization grade 1 insulinoma on histopathology. Given the high surgical risk, we performed a EUS-RFA with 13 sequential ablations. Blood glucose normalized within 48 hours postprocedure. The lesion reduced significantly in size, with no recurrence of hypoglycemia observed up to an 18-month follow-up. EUS-RFA offers a safe and effective alternative to surgery for insulinoma in medically vulnerable patients.

30 March 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
HAHamza Almusabeh
Hamza Almusabeh
JSJoseph Simmons
Joseph Simmons
KEKhaled Elfert
Khaled Elfert
KTKanwarpreet Tandon
Kanwarpreet Tandon

13 April 2026 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
HAHamza Almusabeh
Hamza Almusabeh
MAMohamad Alzaher
Mohamad Alzaher
MVMegan Vaughan
Megan Vaughan
DTDaniel Teran
Daniel Teran
ZKZachary Kovac
Zachary Kovac
KTKanwarpreet Tandon
Kanwarpreet Tandon
Anti–tumor necrosis factor (TNF) agents are widely used for inflammatory bowel disease and have well-documented heart failure risk, but comparative cardiac safety remains uncertain. We conducted a retrospective cohort study using the TriNetX US national database. Adults with Crohn’s disease or ulcerative colitis initiating infliximab or adalimumab were included. Patients with prior heart failure were excluded. The primary outcome was heart failure occurring ≥ 6 months after anti-TNF initiation. Propensity score matching was performed to balance baseline covariates. Before matching, 25,582 patients received infliximab and 24,301 received adalimumab. After matching, 21,554 remained in each group. Median follow-up was ≈ 3.65 years (infliximab) and ≈ 3.91 years (adalimumab). Heart failure occurred in 466 (2.21%) infliximab patients vs 383 (1.81%) adalimumab patients (risk ratio, 1.22; 95% confidence interval [CI] 1.068–1.395; P = 0.003). In an exploratory Cox model, infliximab was associated with a higher heart failure hazard, 1.179 (95% CI 1.029–1.35), and a significant Kaplan-Meier curve by log-rank test (P = 0.02). In this national database analysis of patients with inflammatory bowel disease, infliximab was associated with a higher observed risk of incident heart failure compared with adalimumab.

1 January 2021 in International Journal of Medicine in Developing Countries
Verified
Journal Article
Closed access
ZAZainab AlHashim
Zainab AlHashim
MAMohamad Alzaher
Mohamad Alzaher
AAAli Almulla
Ali Almulla
HAHamza Almusabeh
Hamza Almusabeh
MFMohammad Fehaid
Mohammad Fehaid